To establish whether the mechanism of action of Nano-PSO in the AD model indeed results from inhibition of calpain activity, we looked into the levels of p25, the calpain product which binding to CDK5 results in deregulation of this important enzyme, eventually leading to neurodegeneration46–48. The gene discussed is CDK5; the disease is Alzheimer disease.